Turn Therapeutics Inc.
No enriched coverage for $TTRX in the last 7 days.
No SEC Form 4 filings for $TTRX in the last 30 days.
See all $TTRX insider activity →Turn Therapeutics Inc. (TTRX) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities. As previously disclosed, on October 8, 2025, Turn Therapeutics Inc. (the “Company”) issued to GEM Yield Bahamas Limited a warrant (the “Warrant”) to purchase 1,192,207 shares of the Company’s common stock, par value $0.0001 per s
Turn Therapeutics Inc. (TTRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results Interim Analysis Supports Expansion of GX-03 Phase 2 Study to a Broader Population of Atopic Dermatitis Patients, Including Patients with Moderate-to-Severe Lesions but Low
Biotech gainers included Zhengye Biotechnology (ZYBT), up about 1,048% after a Nasdaq bid-price noncompliance notice. Advanced Biomed (ADVB) rose over 70% after withdrawing a planned SEC-registered offering. Neuronetics (STIM) gained after naming a new CFO. Armata Pharmaceuticals (ARMP) advanced on Phase 3 AP-SA02 progress. Other movers: Profusa (PFSA), Ridgetech (RDGT), Turn Therapeutics (TTRX).
Recent TTRX coverage spans financial news, market movers and technology.
The filing signals near-term dilution risk from warrant cashless exercise, with potential overhang on shares outstanding.
GX-03 interim efficacy separation supports expanding the atopic dermatitis Phase 2 Stage 2, while cash runway guidance reduces near-term financing risk.
Interim efficacy across a broader severity range supports an expansion of the Phase 2 study design.
Expanded patient inclusion and interim efficacy/tolerability support a more comprehensive Stage 2 design, which can de-risk near-term trial execution and readout expectations.
Interim efficacy/tolerability data increases perceived probability of clinical success and supports near-term momentum in TTRX.
alphai scores every news story that mentions TTRX with an AI model for sentiment and relevance, and aggregates insider trades from Turn Therapeutics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Turn Therapeutics Inc. (TTRX) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities. As previously disclosed, on October 8, 2025, Turn Therapeutics Inc. (the “Company”) issued to GEM Yield Bahamas Limited a warrant (the “Warrant”) to purchase 1,192,207 shares of the Company’s common stock, par value $0.0001 per s
2 min readTurn Therapeutics Inc. (TTRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results Interim Analysis Supports Expansion of GX-03 Phase 2 Study to a Broader Population of Atopic Dermatitis Patients, Including Patients with Moderate-to-Severe Lesions but Low
6 min readBiotech gainers included Zhengye Biotechnology (ZYBT), up about 1,048% after a Nasdaq bid-price noncompliance notice. Advanced Biomed (ADVB) rose over 70% after withdrawing a planned SEC-registered offering. Neuronetics (STIM) gained after naming a new CFO. Armata Pharmaceuticals (ARMP) advanced on Phase 3 AP-SA02 progress. Other movers: Profusa (PFSA), Ridgetech (RDGT), Turn Therapeutics (TTRX).
6 min readTurn Therapeutics (TTRX) shares rose 3.8% premarket after expanding its GX-03 Phase 2 atopic dermatitis trial to a broader EASI severity population. The company completed an interim analysis and said efficacy was seen in mild-to-moderate patients (EASI 1.1–7.0), with 71.4% vs 33.3% vehicle achieving Week 4 vIGA-AD success. Final design targets ~120–135 patients; no treatment-related serious AEs reported.
3 min readTurn Therapeutics (TTRX) reported interim Phase 2 data for GX-03 in 50 adults with moderate-to-severe atopic dermatitis. According to the company, 92.6% of GX-03 patients achieved EASI-50 at Week 4 vs 65.2% with vehicle; EASI-90 was 44.4% vs 30.4% at Week 4 and 51.9% vs 34.8% at Week 8. No treatment-related serious adverse events were reported.
4 min readTurn Therapeutics (TTRX) rose over 20% after interim Phase 2 results for GX-03 in atopic dermatitis, with 92.6% achieving EASI-50 at 4 weeks. Conexeu (CNXU) gained ~19% on preclinical B.R.E.A.S.T. bioprinting progress. Rallybio (RLYB) jumped on plans to acquire Avenzo via a $215M investment. LIXTE (LIXT) surged on an AI energy pivot; Quanterix (QTRX) rose on insider SEC filing.
7 min readTurn Therapeutics has secured up to $25 million in growth capital financing from Avenue Capital Group to advance its clinical programs for atopic dermatitis and onychomycosis, with an immediate $7 million tranche. The funding is expected to extend the company's financial runway through the mid-year readout of its Phase 2 trial for atopic dermatitis and support preparations for registrational trials of its lead asset, GX-03. Additional funds are contingent on achieving specific clinical and corporate milestones.
3 min readTurn Therapeutics announced corporate and pipeline updates and its 2026 outlook ahead of the 44th Annual J.P. Morgan Healthcare Conference. The company is on track with its Phase 2 trial of GX-03 for atopic dermatitis, expecting interim and topline data in the first half of 2026. Turn Therapeutics also expanded its vaccine pipeline to include an intranasal influenza candidate and anticipates near-term revenue generation in 2026 from its commercial partnership with Medline in wound care.
3 min readLOS ANGELES, Nov. 11, 2025 ( GLOBE NEWSWIRE ) -- Turn Therapeutics Inc. ( NASDAQ:TTRX ) , a clinical-stage biotechnology company developing dermatologic, advanced wound, and infectious disease therapies, today announced that Chief Executive Officer, Brad Burnam, spoke with Dr. Robert Redfield, ...
3 min readTurn's Topical IL36/IL31 Inhibitor Named Alongside Other Phase 2 & 3 Candidates from Amgen, Sanofi, Leo Pharma, Apogee Therapeutics, and Nektar Therapeutics Turn's Topical IL36/IL31 Inhibitor Named Alongside Other Phase 2 & 3 Candidates from Amgen, Sanofi, Leo Pharma, Apogee Therapeutics, and ...
2 min read
